Navegando por Palavras-chave "cannabidiol"
Agora exibindo 1 - 4 de 4
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosAntipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in Schizophrenia(Bentham Science Publ Ltd, 2012-11-01) Levin, Raquel [UNIFESP]; Almeida, Valeria [UNIFESP]; Peres, Fernanda Fiel [UNIFESP]; Calzavara, Mariana Bendlin [UNIFESP]; Silva, Neide Derci da [UNIFESP]; Suiama, Mayra Akimi [UNIFESP]; Niigaki, Suzy Tamie [UNIFESP]; Zuardi, Antonio Waldo [UNIFESP]; Hallak, Jaime Eduardo Cecilio; Crippa, Jose Alexandre de Souza; Abilio, Vanessa Costhek [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Universidade de São Paulo (USP); CNPqObjectives: Clinical and neurobiological findings suggest that cannabinoids and their receptors are implicated in schizophrenia. Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa plant, has been reported to have central therapeutic actions, such as antipsychotic and anxiolytic effects. We have recently reported that spontaneously hypertensive rats (SHR) present a deficit in contextual fear conditioning (CFC) that is specifically ameliorated by antipsychotics and aggravated by proschizophrenia manipulations. These results led us to suggest that the CFC deficit presented by SHR could be used as a model to study emotional processing impairment in schizophrenia. The aim of this study is to evaluate the effects of CBD and rimonabant (CB1 receptor antagonist) on the contextual fear conditioning in SHR and Wistar rats (WR). Methods: Rats were submitted to CFC task after treatment with different doses of CBD (experiment 1) and rimonabant (experiment 2). Results: In experiment 1, SHR showed a decreased freezing response when compared to WR that was attenuated by 1 mg/kg CBD. Moreover, all CBD-treated WR presented a decreased freezing response when compared to control rats. In experiment 2, SHR showed a decreased freezing response when compared to WR that was attenuated by 3 mg/kg rimonabant. Discussion: Our results suggest a potential therapeutical effect of CBD and rimonabant to treat the emotional processing impairment presented in schizophrenia. In addition, our results reinforce the anxiolytic profile of CBD.
- ItemAcesso aberto (Open Access)Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?(Frontiers Media Sa, 2018) Peres, Fernanda Fiel [UNIFESP]; Lima, Alvaro C.; Hallak, Jaime E. C.; Crippa, José Alexandre de Souza [UNIFESP]; Silva, Regina Helena da [UNIFESP]; Abilio, Vanessa Costhek [UNIFESP]Movement disorders such as Parkinson's disease and dyskinesia are highly debilitating conditions linked to oxidative stress and neurodegeneration. When available, the pharmacological therapies for these disorders are still mainly symptomatic, do not benefit all patients and induce severe side effects. Cannabidiol is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. Although the studies that investigate the effects of this compound on movement disorders are surprisingly few, cannabidiol emerges as a promising compound to treat and/or prevent them. Here, we review these clinical and pre-clinical studies and draw attention to the potential of cannabidiol in this field.
- ItemAcesso aberto (Open Access)Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats(Frontiers Media Sa, 2016) Peres, Fernanda Fiel [UNIFESP]; Leyin, Raquel [UNIFESP]; Suiama, Mayra Akimi [UNIFESP]; Diana, Mariana Cepollaro [UNIFESP]; Gouvea, Douglas Albuquerque [UNIFESP]; Almeida, Valeria [UNIFESP]; Santos, Camila Mauricio [UNIFESP]; Lungato, Lisandro [UNIFESP]; Zuardi, Antonio W.; Hallak, Jaime E. C.; Crippa, Jose A.; D'Almeida, Vania [UNIFESP]; Silva, Regina Helena da [UNIFESP]; Abilio, Vanessa Costhek [UNIFESP]Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson's disease patients, CBD is able to attenuate the psychotic symptoms induced by L-DOPA and to improve quality of life. Repeated administration of reserpine in rodents induces motor impairments that are accompanied by cognitive deficits, and has been applied to model both tardive dyskinesia and Parkinson's disease. The present study investigated whether CBD administration would attenuate reserpine-induced motor and cognitive impairments in rats. Male Wistar rats received four injections of CBD (0.5 or 5 mg/kg) or vehicle (days 2-5). On days 3 and 5, animals received also one injection of 1 mg/kg reserpine or vehicle. Locomotor activity, vacuous chewing movements, and catalepsy were assessed from day 1 to day 7. On days 8 and 9, we evaluated animals' performance on the plus-maze discriminative avoidance task, for learning/memory assessment. CBD (0.5 and 5 mg/kg) attenuated the increase in catalepsy behavior and in oral movements - but not the decrease in locomotion induced by reserpine. CBD (0.5 mg/kg) also ameliorated the reserpine-induced memory deficit in the discriminative avoidance task. Our data show that CBD is able to attenuate motor and cognitive impairments induced by reserpine, suggesting the use of this compound in the pharmacotherapy of Parkinson's disease and tardive dyskinesia.
- ItemSomente MetadadadosCannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy(Frontiers Media Sa, 2016) Peres, Fernanda F. [UNIFESP]; Levin, Raquel [UNIFESP]; Almeida, Valeria [UNIFESP]; Zuardi, Antonio W.; Hallak, Jaime E.; Crippa, Jose A.; Abilio, Vanessa C. [UNIFESP]Schizophrenia is a severe psychiatric disorder that involves positive, negative and cognitive symptoms. Prepulse inhibition of startle reflex (PPI) is a paradigm that assesses the sensorimotor gating functioning and is impaired in schizophrenia patients as well as in animal models of this disorder. Recent data point to the participation of the endocannabinoid system in the pathophysiology and pharmacotherapy of schizophrenia. Here, we focus on the effects of cannabinoid drugs on the PPI deficit of animal models of schizophrenia, with greater focus on the SHR (Spontaneously Hypertensive Rats) strain, and on the future prospects resulting from these findings.